Brendan Frey

Founder and CIO at Deep Genomics

Speaker

The past two years have ushered in an era of immense promise for artificial intelligence (AI) in the pharmaceutical industry. This new generation of AI – the foundation model – is poised to accelerate drug discovery, uncovering novel targets and therapeutics that would likely not be found otherwise. Brendan Frey, a pioneer in this field, will discuss Deep Genomics' BigRNA, an AI foundation model built to accurately model and predict RNA biology for the formulation of tailored therapeutics. Brendan will give his perspective on the opportunities and challenges that lie ahead, as well as the importance of fostering strong partnerships between traditional pharmaceutical companies and a new emerging class of TechBio companies.